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(10.3%) for amlodipine alone, and 17.5 (10.9%), 17.0
(10.4%), and 15.8 (9.7%) for amlodipine in combin-
ation with 1, 2, or 3 additional medications, respectively.
Observed differences of JNC VI goal attainment were
40%, 45%, 42%, and 45%, respectively. Amlodipine ini-
tiation in all regimens showed statistically signiﬁcant SBP
reduction & goal attainment from baseline (p < 0.001).
CONCLUSIONS: Patients receiving amlodipine as
monotherapy or in combination with other agents had
statistically signiﬁcant and clinically meaningful improve-
ments in SBP outcomes and in JNC VI goal attainment
within 12-months of initiating treatment. Although 
these data must be interpreted within the limitations of
the observational study design, this study suggests that
amlodipine may be used in a variety of therapeutic com-
binations to improve SBP goal attainment among hyper-
tensive adults.
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Pulmonary arterial hypertension (PAH) is a rare, incur-
able and often fatal disorder. Current management
includes conventional therapy, prostacyclin therapy for
more advanced patients, and newer agents such as bosen-
tan, an endothelin antagonist. To date, no systematic
review has assessed these interventions. OBJECTIVE: To
perform a systematic review of the medical interventions
used in the management of PAH. METHODS: A litera-
ture search of EMBASE and MEDLINE was performed
in April 2002 and in November 2002. Data for three
outcome measures; survival, exercise capacity, and right
atrial pressure were extracted. Where possible, data were
segregated according to intervention, the type of PAH and
the NYHA/WHO functional class of patients evaluated
in the studies. RESULTS: The literature search yielded
1503 abstracts. 54 papers were included after ﬁrst pass
assessment. Following second pass assessment 28 papers
were included, and were extracted. An additional four
studies were identiﬁed after running the second literature
search. Three studies met second pass inclusion criteria
and were included in the analysis. Three-year survival
rates were 47% to 76% across all interventions. Mean
changes in right atrial pressure from baseline ranged from
a reduction of 6mmHg with epoprostenol to an increase
of 2mmHg with aerosolised iloprost. Mean changes in
exercise capacity from baseline varied from an increase
of 10m with trepostinil in combination with conventional
therapy to an increase of 142m with epoprostenol. The
endothelin-receptor antagonist, bosentan, was found to
have signiﬁcant beneﬁcial effects on exercise capacity,
right atrial pressure superior to iloprost and in certain
instances comparable to epoprostenol. CONCLUSION:
Quantitative comparisons of the interventions are difﬁ-
cult within the context of this review, but the homogene-
ity of the data may make meta-analysis of the evidence
possible in certain circumstances. To make the most valu-
able comparison, long-term data is needed, in particular
assessing mortality.
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OBJECTIVE: Treatment of PPH considers four func-
tional classes. All classes can be managed by medical
therapy. However, recalcitrant class III and IV patients 
are managed by lung transplantation. This study com-
pares the cost-utility of these treatment modalities.
METHODS: Decision modeling is used to evaluate a cost-
utility of treatment modalities for PPH. From 2000 to
2002, 139 patients were evaluated for pulmonary hyper-
tension (PH) at OSU HLRI. Thirty-nine had PPH, 34 had
secondary PH, and the remainder was negative for PH.
Concentrating on the PPH population, 2 died without
treatment, 1 was not interested in treatment, 2 were func-
tional class III/IV and were evaluated for lung transplan-
tation, 12 were started on Flolan, and the rest on Tracleer
and Flolan/Tracleer combination. Probabilities for 
treatment modality choice were calculated based on 
these numbers. Life expectancy and utilities for patients
on Flolan, Tracleer and lung transplant recipients were
obtained from prior studies. Given the probabilities, life
expectancy and utilities, QALYs were calculated as Prob-
ability X Utility X Life Expectancy. The costs for therapy
were annual direct cost for Flolan ($70,000–100,000),
Tracleer ($100/day) and Transplantation ($150,000–
250,000, surgery alone). For simplicity, no other costs
were considered. RESULTS: Patients on Flolan alone had
1.16 QALYs, those on Tracleer or Tracleer/Flolan com-
bination had 2.6 QALYs. On Average, medical therapy
yields 1.88 QALYs. Reported QALYs for all lung trans-
plant recipients is 5.2. Cost/QALY for Flolan ranges
$60,344–86,206; that for Tracleer $14,038; Tracleer/
Flolan combination $26,250; and for lung transplanta-
tion, $61,000 follow-up cost/QALY gained, reported for
Netherlands lung transplantation studies. CONCLU-
SIONS: Tracleer is an orally active endothelin receptor
antagonist that is promising in the treatment for PPH. Its
associated low Cost/QALY makes it attractive over Flolan
alone or lung transplantation. Early diagnosis of PPH and
its treatment by Tracleer and Tracleer/Flolan combination
is cost saving and promising.
